Thanks for emailing that article!
In 2019, Glaucoma Research Foundation launched the Catalyst for a Cure (CFC) Vision Restoration Initiative with a goal to better understand what specifically causes vision loss in glaucoma and then to identify targeted interventions for protecting and restoring the neurons responsible for vision.
This is the third team of CFC investigators funded by Glaucoma Research Foundation. The team’s research will build on discoveries made by the first two CFC teams and their collaboration will intensify the search for new genetic, neuroprotective, and cell replacement therapies for glaucoma.
The Catalyst for a Cure consortium is a team of four principal investigators and their laboratories working together to accelerate the pace of discovery toward a cure for glaucoma.
Different from typical research models where scientists work individually and often compete for grant money, Catalyst for a Cure scientists are engaged in a research collaboration that builds on their collective strengths. By design, their multi-disciplinary skills and efforts will enable them to move more quickly toward their goal.
The CFC Vision Restoration team met with their scientific advisors in February 2019 and have since established their initial plans for working collaboratively on multiple strategies toward vision restoration in glaucoma that they will pursue in the year ahead. The team identified several specific aims for their research and set milestones toward achieving them.
“Glaucoma is the leading cause of irreversible blindness, affecting tens of millions of people. But right now, we have nothing to restore vision. Glaucoma Research Foundation will change that.”
- Jeffrey L. Goldberg, MD, PhD (CFC Scientific Advisory Board member)
Currently, glaucoma is treated by lowering the pressure in the eye. However, today’s treatments can only preserve remaining vision; they don’t improve or restore vision that already has been lost due to glaucoma.
Glaucoma is a complex disease in which damage to the optic nerve leads to progressive vision loss. The nervous system is divided into the peripheral and the central systems, and the optic nerve is part of the central nervous system. Damaged peripheral nerves, in the arm for example, can regenerate after injury. However, the optic nerve and its axons, as part of the central nervous system, do not regenerate after injury. This is one reason why restoring vision lost due to glaucoma has been a tremendous challenge.
The goals of the CFC Vision Restoration team are:
At Glaucoma Research Foundation, we have made a serious long-term commitment to collaborative research. Projects are focused on clear goals and useful results. We invest in innovative research to better understand this complex disease and speed the pace of finding a cure for glaucoma. We believe the novel design of the Catalyst for a Cure and the talented scientists it has brought together are our best hope for finding a cure for this devastating disease.
In 2019, the Catalyst for a Cure research team began to pursue exciting leads in vision restoration. The consortium will explore many promising avenues, from optic nerve regeneration to transplantation to gene manipulation, toward the goal of restoring useful sight to patients who have lost vision to glaucoma.
Xin Duan, PhD
Assistant Professor, Department of Ophthalmology and Physiology
Weill Institute for Neurosciences
University of California, San Francisco
Dr. Duan's laboratory investigates retinal ganglion cells subtype-intrinsic factors and tests their roles in optic nerve regeneration and vision recovery.
Yang Hu, MD, PhD
Assistant Professor, Department of Ophthalmology
Stanford University School of Medicine
The Hu laboratory focuses on the mechanisms responsible for neuronal degeneration and axon regeneration while maintaining a consistent focus on clinically relevant scenarios and therapies that will translate into effective vision restoration treatments.
Anna La Torre, PhD
Assistant Professor, Department of Cell Biology and Human Anatomy
School of Medicine, University of California, Davis
Dr. La Torre’s laboratory focuses on generating retinal ganglion cells from stem cells to enhance axonal growth and cell survival and ultimately, to use these cells as donor cells for cell replacement therapies and disease modeling.
Derek Welsbie, MD, PhD
Assistant Professor of Ophthalmology, San Diego Shiley Eye Institute
University of California, San Diego
San Diego, CA
The Welsbie lab focuses on identifying genes that are causally involved in retinal ganglion cell death, degeneration, and regeneration, as well as developing new neuroprotective drug therapies for retinal ganglion cells.
Last reviewed on May 21, 2019